Clinical Trials Logo

PI3K Gene Mutation clinical trials

View clinical trials related to PI3K Gene Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05571670 Recruiting - Cancer Clinical Trials

Bile Acids in Acute Insulin Resistance

Start date: June 10, 2022
Phase:
Study type: Observational

This is a prospective observational study with a primary goal of monitoring changes in circulating bile acid profiles and parameters of glucose and lipid metabolism prior, during, and after cancer treatment with agents that directly impair insulin action: PI3K inhibitors, AKT inhibitors, and mTOR inhibitors. Patients will not receive any cancer treatment specifically for the purposes of this study. Rather, this study will be based on treatment decisions made independently by participants' oncologists according to standard of care or other clinical trial protocol. This study seeks to enroll at least 25 participants each for PI3K inhibitors, mTOR inhibitors and, once available for open-label treatment, AKT inhibitors.

NCT ID: NCT03994796 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Start date: August 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.